Akèy › Nefrit Lupus
Etid klinik pou Nefrit Lupus ap rekrite nan Etazini
33 etid pou Nefrit Lupus ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- New York City, NY10 etid
- Atlanta, GA9 etid
- Chicago, IL9 etid
- Houston, TX8 etid
- Durham, NC8 etid
- Philadelphia, PA7 etid
- San Francisco, CA7 etid
- Boston, MA7 etid
- Aurora, CO5 etid
- St. Louis, MO5 etid
- Miami, FL5 etid
- Jacksonville, FL4 etid
- Charleston, SC4 etid
- Los Angeles, CA4 etid
- Cleveland, OH4 etid
- Charlotte, NC4 etid
- Syracuse, NY4 etid
- Dallas, TX4 etid
- Johns Creek, GA3 etid
- Worcester, MA3 etid
- New Orleans, LA3 etid
- Baltimore, MD3 etid
- Columbus, OH3 etid
- Santa Monica, CA3 etid
- Gainesville, FL3 etid
- Washington, DC3 etid
Pa eta
- Arizona3 etid
- Colorado7 etid
- Florid10 etid
- Georgia11 etid
- Illinois9 etid
- Kalifòni15 etid
- Kansas3 etid
- Lwizyàn5 etid
- Maryland5 etid
- Massachusetts8 etid
- Michigan3 etid
- Minnesota3 etid
- Missouri6 etid
- New Jersey5 etid
- New York16 etid
- North Carolina11 etid
- Ohio7 etid
- Pennsylvania7 etid
- South Carolina4 etid
- Tennessee4 etid
- Texas12 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT06711887CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
Ap rekriteFaz 1/2
Laj 10 a 29 · Tout sèks · Mizajou Sep 24, 2026 · NCT06839976A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
Ap rekriteFaz 2
Laj 16 a 70 · Tout sèks · Mizajou Sep 17, 2026 · NCT07328581VIBRANT: VIB4920 for Active Lupus Nephritis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT05201469Study of Systemic Lupus Erythematosus
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 3 a 120 · Tout sèks · Mizajou Sep 16, 2026 · NCT00001372Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
Ap rekriteFaz 1
Laj 18 a 60 · Tout sèks · Mizajou Sep 14, 2026 · NCT06975787The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
Ap rekriteFaz 2
Laj 8 a 20 · Tout sèks · Mizajou Sep 14, 2026 · NCT05538208A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
Ap rekriteFaz 2
Laj 12 a 70 · Tout sèks · Mizajou Sep 14, 2026 · NCT07570862A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Ap rekriteFaz 1/2
Laj 18 a 70 · Tout sèks · Mizajou Sep 10, 2026 · NCT06897930A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Ap rekriteFaz 1
Laj 18 a 74 · Tout sèks · Mizajou Sep 10, 2026 · NCT07085104A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Ap rekriteFaz 2
Laj 5 a 17 · Tout sèks · Mizajou Sep 3, 2026 · NCT05039619A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Aug 28, 2026 · NCT06925542RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Ap rekriteFaz 1/2
Laj 18 a 65 · Tout sèks · Mizajou Aug 26, 2026 · NCT06121297Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
Ap rekriteFaz 2
Laj 12 a 65 · Tout sèks · Mizajou Aug 24, 2026 · NCT07053800A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
Ap rekriteFaz 2
Laj 16 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT06419205PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
Ap rekriteFaz 4
Laj 18 a 75 · Tout sèks · Mizajou Aug 3, 2026 · NCT07611214Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Jul 30, 2026 · NCT05268289A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Jul 30, 2026 · NCT07201129Wellness & Workforce Solution for Lupus/Lupus Nephritis
Ap rekriteVolontè an sante akeyi
Laj 18 ak plis · Fanm · Mizajou Jul 24, 2026 · NCT06217107A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 14, 2026 · NCT07115745Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT06527872US Zamto-cel Autoimmune Diseases
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 11, 2026 · NCT06708845A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Jun 4, 2026 · NCT06557265Dapagliflozin in Active Lupus Nephritis
Ap rekriteFaz 4
Laj 18 a 70 · Tout sèks · Mizajou May 26, 2026 · NCT07323524A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Ap rekriteFaz 1
Laj 12 a 70 · Tout sèks · Mizajou May 22, 2026 · NCT06308978Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.